Telix Pharmaceuticals Limited TLX · Stock Open Telix Pharmaceuticals Limited in new tab
Telix Pharmaceuticals Limited Analysis (TLX)
Is Telix Pharmaceuticals Limited a good investment? Telix Pharmaceuticals Limited (TLX) is currently trading at 11.97 USD. Market analysts have a consensus price target of 21.06 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 362.50. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Telix Pharmaceuticals Limited is expected to release its next earnings report on Aug. 20, 2026. The market consensus estimate for Forward EPS is 0.18.
Investor FAQ
Does Telix Pharmaceuticals Limited pay a dividend?
No, it does not currently pay a dividend.
What asset class is Telix Pharmaceuticals Limited?
Telix Pharmaceuticals Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 20, 2026. The company currently has a trailing EPS of -0.02.
Company Profile
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Community Discussion